Evidence map›Paper›PMID 25887595›Full record

ArticleBMC immunology2015

The genetic control of immunity to Plasmodium infection.

Audrey V Grant, Christian Roussilhon, Richard Paul, Anavaj Sakuntabhai

Open access · goldAbstract read
In one paragraph

Article in BMC immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. No G6PD A- (G202A) variant detected amongMalariaWorld journal · 2026
    Article
  3. Article
  4. Article
  5. PeerJ · 2022
    Article
  6. Susceptibility toFrontiers in immunology · 2020
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Frequency ofMediators of inflammation · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Audrey V GrantUnité de la Génétique Fonctionnelle des Maladies Infectieuses, Institut Pasteur, Paris, France. audrey.grant@pasteur.fr.
Christian RoussilhonUnité de la Génétique Fonctionnelle des Maladies Infectieuses, Institut Pasteur, Paris, France. roussilo@pasteur.fr.
Richard PaulUnité de la Génétique Fonctionnelle des Maladies Infectieuses, Institut Pasteur, Paris, France. richard.paul@pasteur.fr.
Anavaj SakuntabhaiUnité de la Génétique Fonctionnelle des Maladies Infectieuses, Institut Pasteur, Paris, France. anavaj@pasteur.fr.
Institut Pasteur · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalaria remains a major worldwide public health problem with ~207 million cases and ~627,000 deaths per year, mainly affecting children under five years of age in Africa. Recent efforts at elaborating a genetic architecture of malaria have focused on severe malaria, leading to the identification of two new genes and confirmation of previously known variants in HBB, ABO and G6PD, by exploring the whole human genome in genome-wide association (GWA) studies. Molecular pathways controlling phenotypes representing effectiveness of host immunity, notably parasitemia and IgG levels, are of particular interest given the current lack of an efficacious vaccine and the need for new treatment options.

resultsWe propose a global causal framework of malaria phenotypes implicating progression from the initial infection with Plasmodium spp. to the development of the infection through liver and blood-stage multiplication cycles (parasitemia as a quantitative trait), to clinical malaria attack, and finally to severe malaria. Genetic polymorphism may control any of these stages, such that preceding stages act as mediators of subsequent stages. A biomarker of humoral immunity, IgG levels, can also be integrated into the framework, potentially mediating the impact of polymorphism by limiting parasitemia levels. Current knowledge of the genetic basis of parasitemia levels and IgG levels is reviewed through key examples including the hemoglobinopathies, showing that the protective effect of HBB variants on malaria clinical phenotypes may partially be mediated through parasitemia and cytophilic IgG levels. Another example is the IgG receptor FcγRIIa, encoded by FCGR2A, such that H131 homozygotes displayed higher IgG2 levels and were protective against high parasitemia and onset of malaria symptoms as shown in a causal diagram.

conclusionsWe thus underline the value of parasitemia and IgG levels as phenotypes in the understanding of the human genetic architecture of malaria, and the need for applying GWA approaches to these phenotypes.

Indexed as

Malaria VaccinesABO Blood-Group SystemAnimalsChild, PreschoolGenome-Wide Association StudyGlucosephosphate DehydrogenaseHumansImmunity, HumoralMalariaMalaria, FalciparumParasitemiaABO Blood-Group SystemGlucosephosphate DehydrogenaseMalaria Vaccines

Identifiers

PMID25887595
PMCPMC4374205
OpenAlexW1981071671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.